LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 10

Search options

  1. Article ; Online: Epidemiology and Mycology of Candidaemia in non-oncological medical intensive care unit patients in a tertiary center in the United States: Overall analysis and comparison between non-COVID-19 and COVID-19 cases.

    Macauley, Precious / Epelbaum, Oleg

    Mycoses

    2021  Volume 64, Issue 6, Page(s) 634–640

    Abstract: The epidemiology and mycology of invasive candidiasis in the ICU is well-described in certain types of critically ill patients but not in others. One population that has been scarcely studied is non-neutropenic patients admitted specifically to medical ... ...

    Abstract The epidemiology and mycology of invasive candidiasis in the ICU is well-described in certain types of critically ill patients but not in others. One population that has been scarcely studied is non-neutropenic patients admitted specifically to medical ICUs. Even less is known about the broader category of medical ICU patients without active oncological disease. This group constitutes a very large share of the patients requiring critical care across the globe, especially in the era of the SARS-CoV-2 pandemic. We analysed medical ICU candidaemia episodes that occurred in non-oncological patients in our tertiary academic centre in the United States from May 2014 to October 2020 to determine the incidence and species distribution of the associated isolates. We then separately considered non-COVID-19 and COVID-19 cases and compared their characteristics. In the non-COVID-19 group, there were 38 cases for an incidence of 1.1% and rate of 11/1000 admissions. In the COVID-19 group, there were 12 cases for an incidence of 5.1% and rate of 51/1000 admissions. In the entire sample, as well as separately in the non-COVID-19 and COVID-19 groups,Candida albicans accounted for a minority of isolates. Compared to non-COVID-19 patients with candidaemia, COVID-19 patients had lower ICU admission SOFA score but longer ICU length of stay and central venous catheter dwell time at candidaemia detection. This study provides valuable insight into the incidence and species distribution of candidaemia cases occurring in non-oncological critically ill patients and identifies informative differences between non-COVID-19 and COVID-19 patients.
    MeSH term(s) Adult ; Aged ; COVID-19/epidemiology ; COVID-19/microbiology ; Candida/isolation & purification ; Candidemia/epidemiology ; Candidemia/microbiology ; Candidemia/virology ; Critical Care ; Critical Illness ; Female ; Humans ; Incidence ; Intensive Care Units ; Male ; Middle Aged ; SARS-CoV-2/isolation & purification ; Tertiary Care Centers ; United States/epidemiology
    Language English
    Publishing date 2021-03-08
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 392487-7
    ISSN 1439-0507 ; 0933-7407
    ISSN (online) 1439-0507
    ISSN 0933-7407
    DOI 10.1111/myc.13258
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: CORTICOSTEROIDS IN THE TREATMENT OF SEVERE COVID-19 LUNG DISEASE: THE PULMONOLOGY PERSPECTIVE FROM THE FIRST UNITED STATES EPICENTER.

    Macauley, Precious / Martin, Alvaro / Epelbaum, Oleg

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

    2020  Volume 100, Page(s) 309–313

    Abstract: The SARS-CoV-2 pandemic has introduced the medical community to a lung disease heretofore unknown to most clinicians. In much of the discourse about COVID-19 lung disease, the more familiar clinical entity of ARDS has been used as the guiding paradigm. ... ...

    Abstract The SARS-CoV-2 pandemic has introduced the medical community to a lung disease heretofore unknown to most clinicians. In much of the discourse about COVID-19 lung disease, the more familiar clinical entity of ARDS has been used as the guiding paradigm. Reflecting on studies in ARDS, particularly that due to influenza, and on data from the SARS-CoV and MERS epidemics, many authorities, including within the discipline of infectious diseases, were initially passionate in their opposition to the use of corticosteroids for lung involvement in COVID-19. The voice of the pulmonology community-the community of lung experts-has continued to be among the quietest in this conversation. Herein we offer our perspective as academic pulmonologists who encountered COVID-19 in its first United States epicenter of New York City. We encourage a conceptual separation between early COVID-19 lung involvement and ARDS. We draw on history with other immune cell-mediated lung diseases, on insights from the SARS-CoV experience, and on frontline observations in an attempt to allay the skepticism towards corticosteroids in COVID-19 lung disease that is likely to persist even as favorable study results emerge.
    MeSH term(s) COVID-19/drug therapy ; COVID-19/epidemiology ; Humans ; Pandemics ; Pulmonary Medicine ; SARS-CoV-2 ; United States
    Keywords covid19
    Language English
    Publishing date 2020-08-21
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 1331197-9
    ISSN 1878-3511 ; 1201-9712
    ISSN (online) 1878-3511
    ISSN 1201-9712
    DOI 10.1016/j.ijid.2020.08.051
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Corticosteroids in the treatment of severe COVID-19 lung disease

    Precious Macauley / Alvaro Martin / Oleg Epelbaum

    International Journal of Infectious Diseases, Vol 100, Iss , Pp 309-

    The pulmonology perspective from the first United States epicenter

    2020  Volume 313

    Abstract: The SARS-CoV-2 pandemic has introduced the medical community to a lung disease heretofore unknown to most clinicians. In much of the discourse about COVID-19 lung disease, the more familiar clinical entity of acute respiratory distress syndrome (ARDS) ... ...

    Abstract The SARS-CoV-2 pandemic has introduced the medical community to a lung disease heretofore unknown to most clinicians. In much of the discourse about COVID-19 lung disease, the more familiar clinical entity of acute respiratory distress syndrome (ARDS) has been used as the guiding paradigm. Reflecting on studies in ARDS, particularly that caused by influenza, and on data from the SARS-CoV and MERS epidemics, many authorities, including those within the discipline of infectious diseases, were initially passionate in their opposition to the use of corticosteroids for lung involvement in COVID-19. The voice of the pulmonology community—the community of lung experts—has continued to be among the quietest in this conversation. Herein we offer our perspective as academic pulmonologists who encountered COVID-19 in its first United States epicenter of New York City. We encourage a conceptual separation between early COVID-19 lung involvement and ARDS. We draw on history with other immune cell-mediated lung diseases, on insights from the SARS-CoV experience, and on frontline observations in an attempt to allay the skepticism towards corticosteroids in COVID-19 lung disease that is likely to persist even as favorable study results emerge.
    Keywords COVID-19 ; Coronavirus ; Corticosteroids ; SARS ; ARDS ; Infectious and parasitic diseases ; RC109-216 ; covid19
    Subject code 610
    Language English
    Publishing date 2020-11-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: CORTICOSTEROIDS IN THE TREATMENT OF SEVERE COVID-19 LUNG DISEASE

    Macauley, Precious / Martin, Alvaro / Epelbaum, Oleg

    International Journal of Infectious Diseases

    THE PULMONOLOGY PERSPECTIVE FROM THE FIRST UNITED STATES EPICENTER

    2020  Volume 100, Page(s) 309–313

    Keywords Microbiology (medical) ; Infectious Diseases ; General Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 1331197-9
    ISSN 1878-3511 ; 1201-9712
    ISSN (online) 1878-3511
    ISSN 1201-9712
    DOI 10.1016/j.ijid.2020.08.051
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article: Corticosteroids in the treatment of severe COVID-19 lung disease: The pulmonology perspective from the first United States epicenter

    Macauley, Precious / Martin, Alvaro / Epelbaum, Oleg

    Int J Infect Dis

    Abstract: The SARS-CoV-2 pandemic has introduced the medical community to a lung disease heretofore unknown to most clinicians. In much of the discourse about COVID-19 lung disease, the more familiar clinical entity of acute respiratory distress syndrome (ARDS) ... ...

    Abstract The SARS-CoV-2 pandemic has introduced the medical community to a lung disease heretofore unknown to most clinicians. In much of the discourse about COVID-19 lung disease, the more familiar clinical entity of acute respiratory distress syndrome (ARDS) has been used as the guiding paradigm. Reflecting on studies in ARDS, particularly that caused by influenza, and on data from the SARS-CoV and MERS epidemics, many authorities, including those within the discipline of infectious diseases, were initially passionate in their opposition to the use of corticosteroids for lung involvement in COVID-19. The voice of the pulmonology community-the community of lung experts-has continued to be among the quietest in this conversation. Herein we offer our perspective as academic pulmonologists who encountered COVID-19 in its first United States epicenter of New York City. We encourage a conceptual separation between early COVID-19 lung involvement and ARDS. We draw on history with other immune cell-mediated lung diseases, on insights from the SARS-CoV experience, and on frontline observations in an attempt to allay the skepticism towards corticosteroids in COVID-19 lung disease that is likely to persist even as favorable study results emerge.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #724989
    Database COVID19

    Kategorien

  6. Article: Miliary Tuberculosis Presenting With Meningitis in a Patient Treated With Mycophenolate for Lupus Nephritis: Challenges in Diagnosis and Review of the Literature.

    Macauley, Precious / Rapp, Mark / Park, Sarah / Lamikanra, Olaoluwatomi / Sharma, Pratibha / Marcelin, Michael / Sharma, Kavita

    Journal of investigative medicine high impact case reports

    2018  Volume 6, Page(s) 2324709618770226

    Abstract: Tuberculosis is one of the top 10 causes of death worldwide according to the World Health Organization. Central nervous system involvement is usually the least common presentation of tuberculosis occurring in about 1% of all cases but yet can have very ... ...

    Abstract Tuberculosis is one of the top 10 causes of death worldwide according to the World Health Organization. Central nervous system involvement is usually the least common presentation of tuberculosis occurring in about 1% of all cases but yet can have very devastating outcomes. Lupus nephritis is one of the most common complications of systemic lupus erythematosus with up to two thirds of patients presenting with some degree of renal dysfunction. The mainstay of treatment is glucocorticoids; however, to sustain remission, steroid sparing agents such as cyclophosphamide, azathioprine and mycophenolate mofetil are used. Such patients, in addition to their baseline dysfunctional immune system, have a heightened risk of infections due to these drugs. In this article, we present a young woman who had recently been started on mycophenolate mofetil for control of class V lupus nephritis who presented with headaches, sinus pressure, and fevers. She had a protracted course of hospitalization as she failed to improve clinically and to respond to conventional therapy for acute bacterial sinusitis and meningitis. She was empirically started on antitubercular therapy 9 days after hospitalization. The diagnosis was not confirmed until day 18, the day results of cerebrospinal fluid acid-fast
    Language English
    Publishing date 2018-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2710326-2
    ISSN 2324-7096
    ISSN 2324-7096
    DOI 10.1177/2324709618770226
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Bilateral Femoral Neuropathy Following Psoas Muscle Hematomas Caused by Enoxaparin Therapy.

    Macauley, Precious / Soni, Parita / Akkad, Isaac / Demir, Selma / Shankar, Shyam / Kakar, Parul / Bhardwaj, Sharonlin

    The American journal of case reports

    2017  Volume 18, Page(s) 937–940

    Abstract: BACKGROUND Femoral neuropathy as a result of retroperitoneal hemorrhage most commonly occurs following pelvic and lower extremity trauma, but has been described to develop as a less frequent complication of anticoagulation. CASE REPORT We present the ... ...

    Abstract BACKGROUND Femoral neuropathy as a result of retroperitoneal hemorrhage most commonly occurs following pelvic and lower extremity trauma, but has been described to develop as a less frequent complication of anticoagulation. CASE REPORT We present the case of a 64-year-old white woman who was being treated for pulmonary embolism and deep venous thrombosis with enoxaparin. In the course of her treatment, she was noted to be hypotensive, with a sudden drop in hematocrit. She had been previously ambulatory, but noted an inability to move her bilateral lower extremities. A diagnosis of bilateral femoral neuropathy as a result of psoas hematomas caused by enoxaparin was made. Anticoagulation was discontinued and she was treated conservatively, with an excellent outcome. At the time of discharge to a rehabilitation center, she had regained most of the motor strength in her lower extremities. CONCLUSIONS We believe this is the first reported case of bilateral femoral nerve neuropathy following use of enoxaparin. A full neurological examination should always be performed when there is sudden loss of function. The constellation of bilateral groin pain, loss of lower extremity mobility, and decreased hematocrit raised the suspicion of massive blood loss into the cavity/compartment. Thus, a high index of suspicion should be maintained by clinicians when presented with such symptoms and signs, as there can be significant morbidity and mortality when prompt diagnosis is not made.
    MeSH term(s) Anticoagulants/adverse effects ; Enoxaparin/adverse effects ; Female ; Femoral Neuropathy/etiology ; Hematoma/chemically induced ; Hematoma/complications ; Hematoma/diagnostic imaging ; Humans ; Middle Aged ; Psoas Muscles/diagnostic imaging ; Pulmonary Embolism/drug therapy ; Venous Thrombosis/drug therapy
    Chemical Substances Anticoagulants ; Enoxaparin
    Language English
    Publishing date 2017-08-29
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2517183-5
    ISSN 1941-5923 ; 1941-5923
    ISSN (online) 1941-5923
    ISSN 1941-5923
    DOI 10.12659/ajcr.904975
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Hemophagocytic Lymphohistiocytosis Associated With Parvovirus B19 in a Patient With Acquired Immunodeficiency Syndrome.

    Macauley, Precious / Abu-Hishmeh, Mohammad / Dumancas, Carissa / Alexander-Rajan, Vijay / Piedra-Chavez, Fernando / Nada, Khaled / Habtes, Imnett / Popescu, Andrea / Mamorska-Dyga, Aleksandra

    Journal of investigative medicine high impact case reports

    2019  Volume 7, Page(s) 2324709619883698

    Abstract: Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening condition characterized by widespread inflammation due to massive immune activation and cytokine release. It is of 2 types, primary or familial and secondary or acquired. Diagnosis ... ...

    Abstract Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening condition characterized by widespread inflammation due to massive immune activation and cytokine release. It is of 2 types, primary or familial and secondary or acquired. Diagnosis is made by fulfilling 5 of 8 criteria as determined by the Histiocyte Society. Treatment includes etoposide, dexamethasone, with or without intrathecal methotrexate in the presence of neurologic involvement as well as treating the underlying cause in secondary HLH. We present a case of a 23-year-old female with congenital human immunodeficiency virus (HIV) infection who presents with nonspecific signs and symptoms of cough, fever, leukopenia, and anemia, and a high-serum parvovirus B19 DNA, later diagnosed with HLH and treated with etoposide and dexamethasone. She made clinical improvements and was successfully discharged to home after 26 days of admission.
    MeSH term(s) AIDS-Related Opportunistic Infections/diagnosis ; Acquired Immunodeficiency Syndrome/congenital ; Dexamethasone/administration & dosage ; Dexamethasone/therapeutic use ; Drug Therapy, Combination ; Etoposide/administration & dosage ; Etoposide/therapeutic use ; Female ; Humans ; Lymphohistiocytosis, Hemophagocytic/diagnosis ; Lymphohistiocytosis, Hemophagocytic/drug therapy ; Lymphohistiocytosis, Hemophagocytic/etiology ; Lymphohistiocytosis, Hemophagocytic/virology ; Parvoviridae Infections/complications ; Parvoviridae Infections/diagnosis ; Parvoviridae Infections/etiology ; Parvoviridae Infections/virology ; Parvovirus B19, Human ; Young Adult
    Chemical Substances Etoposide (6PLQ3CP4P3) ; Dexamethasone (7S5I7G3JQL)
    Language English
    Publishing date 2019-10-18
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 2710326-2
    ISSN 2324-7096 ; 2324-7096
    ISSN (online) 2324-7096
    ISSN 2324-7096
    DOI 10.1177/2324709619883698
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Hemophagocytic Lymphohistiocytosis Associated With Parvovirus B19 in a Patient With Acquired Immunodeficiency Syndrome

    Precious Macauley MD / Mohammad Abu-Hishmeh MD / Carissa Dumancas MD / Vijay Alexander-Rajan MD / Fernando Piedra-Chavez MD / Khaled Nada MD / Imnett Habtes MD / Andrea Popescu MD / Aleksandra Mamorska-Dyga MD

    Journal of Investigative Medicine High Impact Case Reports, Vol

    2019  Volume 7

    Abstract: Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening condition characterized by widespread inflammation due to massive immune activation and cytokine release. It is of 2 types, primary or familial and secondary or acquired. Diagnosis ... ...

    Abstract Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening condition characterized by widespread inflammation due to massive immune activation and cytokine release. It is of 2 types, primary or familial and secondary or acquired. Diagnosis is made by fulfilling 5 of 8 criteria as determined by the Histiocyte Society. Treatment includes etoposide, dexamethasone, with or without intrathecal methotrexate in the presence of neurologic involvement as well as treating the underlying cause in secondary HLH. We present a case of a 23-year-old female with congenital human immunodeficiency virus (HIV) infection who presents with nonspecific signs and symptoms of cough, fever, leukopenia, and anemia, and a high-serum parvovirus B19 DNA, later diagnosed with HLH and treated with etoposide and dexamethasone. She made clinical improvements and was successfully discharged to home after 26 days of admission.
    Keywords Medicine (General) ; R5-920 ; Pathology ; RB1-214
    Subject code 616
    Language English
    Publishing date 2019-10-01T00:00:00Z
    Publisher SAGE Publishing
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Miliary Tuberculosis Presenting With Meningitis in a Patient Treated With Mycophenolate for Lupus Nephritis

    Precious Macauley MD / Mark Rapp BSc / Sarah Park BSc / Olaoluwatomi Lamikanra MBBS / Pratibha Sharma MBBS / Michael Marcelin MD / Kavita Sharma MBBS

    Journal of Investigative Medicine High Impact Case Reports, Vol

    Challenges in Diagnosis and Review of the Literature

    2018  Volume 6

    Abstract: Tuberculosis is one of the top 10 causes of death worldwide according to the World Health Organization. Central nervous system involvement is usually the least common presentation of tuberculosis occurring in about 1% of all cases but yet can have very ... ...

    Abstract Tuberculosis is one of the top 10 causes of death worldwide according to the World Health Organization. Central nervous system involvement is usually the least common presentation of tuberculosis occurring in about 1% of all cases but yet can have very devastating outcomes. Lupus nephritis is one of the most common complications of systemic lupus erythematosus with up to two thirds of patients presenting with some degree of renal dysfunction. The mainstay of treatment is glucocorticoids; however, to sustain remission, steroid sparing agents such as cyclophosphamide, azathioprine and mycophenolate mofetil are used. Such patients, in addition to their baseline dysfunctional immune system, have a heightened risk of infections due to these drugs. In this article, we present a young woman who had recently been started on mycophenolate mofetil for control of class V lupus nephritis who presented with headaches, sinus pressure, and fevers. She had a protracted course of hospitalization as she failed to improve clinically and to respond to conventional therapy for acute bacterial sinusitis and meningitis. She was empirically started on antitubercular therapy 9 days after hospitalization. The diagnosis was not confirmed until day 18, the day results of cerebrospinal fluid acid-fast bacillus culture was reported. This case is reported to highlight the challenges in diagnosing Mycobacterium tuberculosis infection in an immunocompromised state and to demonstrate that its presentation can mimic numerous other conditions. Clinicians must maintain a high index of suspicion of Mycobacterium tuberculosis infection in such patients who present with nonspecific or unexplainable symptoms.
    Keywords Medicine (General) ; R5-920 ; Pathology ; RB1-214
    Subject code 610
    Language English
    Publishing date 2018-04-01T00:00:00Z
    Publisher SAGE Publishing
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top